A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.

ABSTRACT:

Context

Increased concentrations of inflammatory biomarkers predict antidepressant nonresponse, and inflammatory cytokines can sabotage and circumvent the mechanisms of action of conventional antidepressants.

Objectives

To determine whether inhibition of the inflammatory cytokine tumor necrosis factor (TNF) reduces depressive symptoms in patients with treatment-resistant depression and whether an increase in baseline plasma inflammatory biomarkers, including high-sensitivity C-reactive protein (hs-CRP), TNF, and its soluble receptors, predicts treatment response.

Design

Double-blind, placebo-controlled, randomized clinical trial.

Setting

Outpatient infusion center at Emory University in Atlanta, Georgia.

Participants

A total of 60 medically stable outpat

SUBMITTER: Raison CL 

PROVIDER: S-EPMC4015348 | biostudies-literature | 2013 Jan

REPOSITORIES: biostudies-literature